Primary hyperparathyroidism

From Wikipedia, the free encyclopedia

Primary hyperparathyroidism
Classification & external resources
Thyroid and parathyroid.
ICD-10 E21.0
ICD-9 252.01
DiseasesDB 6283
eMedicine radio/355 
MeSH D049950

Primary hyperparathyroidism causes hypercalcemia (elevated blood calcium levels) through the excessive secretion of parathyroid hormone (PTH), usually by an adenoma (benign tumors) of the parathyroid glands. Its incidence is approximately 42 per 100,000 people. It is almost exactly three times as common in women as men.

Contents

[edit] Signs and Symptoms

The signs and symptoms of primary hyperparathyroidism are those of hypercalcemia. They are classically summarized by the mnemonic "stones, bones, abdominal groans and psychic moans".

Other signs include proximal muscle weakness, itching, and band keratopathy of the eyes.

[edit] Diagnosis

The diagnosis of primary hyperparathyroidism is made by blood tests. Serum calcium levels are elevated. Intact PTH levels are also elevated. Urinary cAMP is occasionally measured; this is generally elevated.

[edit] Causes

The most common cause of primary hyperparathyroidism is a sporadic, single parathyroid adenoma resulting from a clonal mutation (~97%). Less common are hyperplasia of all parathyroid glands (~2.5%), parathyroid carcinoma (malignant tumor), and adenomas in more than one gland (together ~0.5%). Primary hyperparathyroidism is also a feature of several familial endocrine disorders: Multiple endocrine neoplasia type 1 and type 2A (MEN type 1 and MEN type 2A), and familial hyperparathyroidism.

In all cases, the disease is idiopathic, but is thought to involve inactivation of tumor suppression genes.

[edit] Complications

The classic bone disease in hyperparathyroidism is osteitis fibrosa cystica, which results in pain and sometimes pathological fractures. Other bone diseases associated with hyperparathyroidism are osteoporosis, osteomalacia, and arthritis.

[edit] Treatment

Treatment is usually surgical removal of the gland(s) containing adenomas. Medications (such as estrogen replacement therapy in postmenopausal women and bisphosphonates) thus far have not been very effective. Future developments such as calcimemetic agents (e.g. cinacalcet) which activate the parathyroid calcium-sensing receptor may offer a good alternative to surgery.

[edit] See also

[edit] References

  • Greenspan FS, Gardner DG. Basic & Clinical Endocrinology 7th ed. McGraw-Hill Companies: 2004.
In other languages